Orexo AB (ORX) - Total Assets
Based on the latest financial reports, Orexo AB (ORX) holds total assets worth Skr610.40 Million SEK (≈ $65.69 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Orexo AB (ORX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Orexo AB - Total Assets Trend (2002–2025)
This chart illustrates how Orexo AB's total assets have evolved over time, based on quarterly financial data. Explore how much of Orexo AB's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Orexo AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Orexo AB's total assets of Skr610.40 Million consist of 89.4% current assets and 10.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 70.0% |
| Accounts Receivable | Skr237.40 Million | 18.2% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr56.40 Million | 4.3% |
| Intangible Assets | Skr400.00K | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Orexo AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Orexo AB market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orexo AB's current assets represent 89.4% of total assets in 2025, an increase from 61.1% in 2002.
- Cash Position: Cash and equivalents constituted 70.0% of total assets in 2025, up from 44.7% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 29.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 18.2% of total assets.
Orexo AB Competitors by Total Assets
Key competitors of Orexo AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Orexo AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.03 | 1.73 | 2.77 |
| Quick Ratio | 2.03 | 1.55 | 2.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr241.10 Million | Skr150.20 Million | Skr603.60 Million |
Orexo AB - Advanced Valuation Insights
This section examines the relationship between Orexo AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 119.0% |
| Total Assets | Skr1.30 Billion |
| Market Capitalization | $79.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Orexo AB's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Orexo AB's assets grew by 119.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Orexo AB (2002–2025)
The table below shows the annual total assets of Orexo AB from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr1.30 Billion ≈ $140.20 Million |
+119.03% |
| 2024-12-31 | Skr594.80 Million ≈ $64.01 Million |
-24.38% |
| 2023-12-31 | Skr786.60 Million ≈ $84.65 Million |
-29.07% |
| 2022-12-31 | Skr1.11 Billion ≈ $119.35 Million |
-12.93% |
| 2021-12-31 | Skr1.27 Billion ≈ $137.07 Million |
+3.31% |
| 2020-12-31 | Skr1.23 Billion ≈ $132.68 Million |
-17.87% |
| 2019-12-31 | Skr1.50 Billion ≈ $161.54 Million |
+16.66% |
| 2018-12-31 | Skr1.29 Billion ≈ $138.47 Million |
+28.17% |
| 2017-12-31 | Skr1.00 Billion ≈ $108.04 Million |
-1.46% |
| 2016-12-31 | Skr1.02 Billion ≈ $109.64 Million |
+0.25% |
| 2015-12-31 | Skr1.02 Billion ≈ $109.37 Million |
-17.10% |
| 2014-12-31 | Skr1.23 Billion ≈ $131.92 Million |
+58.73% |
| 2013-12-31 | Skr772.33 Million ≈ $83.12 Million |
+60.32% |
| 2012-12-31 | Skr481.75 Million ≈ $51.84 Million |
-11.78% |
| 2011-12-31 | Skr546.10 Million ≈ $58.77 Million |
-23.37% |
| 2010-12-31 | Skr712.69 Million ≈ $76.70 Million |
+9.76% |
| 2009-12-31 | Skr649.33 Million ≈ $69.88 Million |
-7.51% |
| 2008-12-31 | Skr702.02 Million ≈ $75.55 Million |
-12.45% |
| 2007-12-31 | Skr801.87 Million ≈ $86.29 Million |
+111.06% |
| 2006-12-31 | Skr379.93 Million ≈ $40.89 Million |
+2.32% |
| 2005-12-31 | Skr371.31 Million ≈ $39.96 Million |
+250.24% |
| 2004-12-31 | Skr106.02 Million ≈ $11.41 Million |
+134.80% |
| 2003-12-31 | Skr45.15 Million ≈ $4.86 Million |
+35.80% |
| 2002-12-31 | Skr33.25 Million ≈ $3.58 Million |
-- |
About Orexo AB
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabac… Read more